Regeneron Q2 revenue +16.7% to $4.29B, but net income falls 6.8% on higher costs and lower other income

Filed July 30, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 1, 2025 · ~1 min read

Key Changes

• high

  Total revenue rose 16.7% to $4.29B, driven by Dupixent (up 38%) and EYLEA HD, while net income fell 6.8% to $1.30B.

  MD&A: Revenue and net income verify on EDGAR →
• high

  Operating income rose 20% to $1.3B, but net income declined 6.8% to $1.30B — the divergence driven by a $308.7M swing in below-the-line items (non-operating/other -$204.9M, income tax -$103.8M).

  MD&A: Earnings quality verify on EDGAR →
• high

  New U.S. government agreements impose Most-Favored-Nation pricing on certain products and free provision of gene therapy Otarmeni, potentially pressuring future U.S. revenue.

  MD&A: U.S. government pricing verify on EDGAR →